Журнал кардиореспираторных исследований 2026. №3

Subject of the article

Peripartal kardiomiopatiya bilan assotsirlangan o‘tkir yurak-qon tomir yetishmovchiligini davolashda multimodal yondashuv: intensiv terapiya tamoyillar (16-19)

Authors

Joniev S.Sh.

Institution

Samarqand davlat tibbiyot universiteti

Abstract

Ushbu maqola homiladorlik davrining eng og‘ir asoratlaridan biri — peripartal kardiomiopatiya (PPKMP) fonida rivojlangan shoshilinch holatlarni kompleks davolash masalalariga bag‘ishlangan. Unda o‘tkir yurak yetishmovchiligining klinik manzarasi, zamonaviy diagnostika mezonlari va differensial diagnostika jihatlari batafsil yoritilgan. Reanimatsiya va intensiv terapiya sharoitida yurak-o‘pka yetishmovchiligi darajasini o‘z vaqtida adekvat baholash hamda instrumental tekshiruvlar yordamida tashxisni tasdiqlashning muhimligi asoslab berilgan. Shuningdek, maqolada PPKMP bilan og‘rigan bemorlarni multidistsiplinar yondashuv asosida olib borish bo‘yicha klinik protokollar tahlil qilingan. Gemodinamikasi beqaror bemorlarda shoshilinch terapevtik choralarni qo‘llash, jumladan, katexolaminlar, diuretiklar, levosimendan, bromokriptin va antikoagulyantlar kabi farmakologik vositalarning o‘rni va samaradorligi ko‘rib chiqilgan.

Key words

o’g’ir peripartal kardiomiopatiya; differentsial diagnostika; o‘tkir yurak yetishmovchiligi; reanimatsiya va intensiv terapiya, medikamentoz terapiya, inotroplar

Literature

1. Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation. 2016; 133(14):1397-409. doi: 10.1161/Circulationaha.115.020491. 2. Arrigo M, Mebazaa A. Understanding the differences among inotropes. Intensive Care Med. 2019; 41: 912–5. doi: 10.1007/s00134-015- 3659-7. 3. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJ, Crespo-Leiro MG, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016; 18(9): 1096-105. doi: 10.1002/ejhf.586. 4. Bouabdallaoui N, Mouquet F, Lebreton G, Demondion P, Le Jemtel TH, Ennezat PV. Current knowledge and recent development on management of peripartum cardiomyopathy. Eur Heart J Acute Cardiovasc Care.2017;6(4):359-366. doi: 10.1177/2048872615612465. 5. Bhattacharyya A, Basra SS, Sen P, Kar B. Peripartum cardiomyopathy: a review. Tex Heart Inst J. 2022; 39(1): 8-16. 6. Dinic V, Markovic D, Savic N, Kutlesic M, Jankovic RJ. Peripartum cardiomyopathy in intensive care unit: an update. Front Med (Lausanne). 2019; 2: 82. doi: 10.3389/ fmed.2015.00082. 7. Duncker D, Haghikia A, König T, Hohmann S, Gutleben K-J, Westenfeld R, et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function: value of the wearable cardioverter/defibrillator. Eur J Heart Fail. 2024; 16(12):1331-6. doi: 10.1002/ejhf.188. 8. Fett JD. Caution in the use of bromocriptine in peripartum cardiomyopathy. J Am Coll Cardiol. 2018; 51: 2083. doi:10.1016/j.jacc.2008.02.054. 9. Fett JD. Peripartum cardiomyopathy: challenges in diagnosis and management. Expert Rev Cardiovasc Ther. 2016; 14(9): 1035–41. doi: 10.1080/14779072.2016.1199273. 10. Fuller KP, Turner G, Polavarapu S, Prabulos AM. Guidelines for use of anticoagulation in pregnancy. Clin Lab Med. 2023;33(2):343- 56. doi: 10.1016/j. cll.2013.03.018. 11. Joniev S.Sh., Obloberdiyev M. "Optimization of intensive care in critical conditions in patients with peripartum cardiomyopathy" [Текст] / Joniev S.Sh., Obloberdiyev M. // Journal of new century innovations. — 2026. — № 2. — С. 149-151. 12. Joniev S.Sh., Obloberdiyev M. Periportal kardiomiopatiyalarda o'tkir yurak yetishmovchiligini intensiv terapiyasi samaradorligini oshirish [Текст] / Joniev S.Sh., Obloberdiyev M. // Лучшие интелектуальные исследования. — 2026. — № Часть 62 Том-4. — С. 277-284. 13. Garg J, Palaniswamy C, Lanier GM. Peripartum cardiomyopathy: definition, incidence, etiopathogenesis, diagnosis, and management. Cardiol Rev. 2015; 23(2):69-78. doi: 10.1097/CRD.0000000000000038. 14. Hamdan R, Nassar P, Zein A, Issa M, Mansour H, Saab M. Peripartum cardiomyopathy, place of drug therapy, assist devices, and outcome after left ventricular assistance. J Crit Care. 2017;37:185-8. doi: 10.1016/j.jcrc.2016.09.028. 15. Hasan JA, Qureshi A, Ramejo BB, Kamran A. Peripartum cardiomyopathy characteristics and outcome in a tertiary care hospital. J Pak Med Assoc. 2010;60:377–80. 16. Hilfiker-Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol. 2014; 11(6):364-70. doi: 10.1038/ nrcardio.2014.37. 17. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 2015; 36(18): 1090–7. doi: 10.1093/eurheartj/ehv009. 18. Hilfiker-Kleiner D, Westhoff-Bleck M, Gunter H-H, Kaisenbergvon CS, Bohnhorst B, Hoeltje M, et al. A manage-103 ment algorithm for acute heart failure in pregnancy. The Hannover experience. Eur Heart J. 2015; 36(13):769–70. 19. Isezuo SA, Abubakar SA. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. Ethn Dis. 2007;17:228–33. 20. Kim MJ, Shin MS. Practical management of peripartum cardiomyopathy. Korean J Intern Med. 2017 Apr 14. doi:10.3904/kjim.2016.360. 21. Kolte D, Khera S, AronowWS, Palaniswamy C, Mujib M, Ahn C, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population based study. 2014 Jun 4;3(3):e001056. doi: 10.1161/JAHA.114.001056. 22. Krejčí J, Poloczková H, Nĕmec P. Current therapeutic concepts in peripartum cardiomyopathy. Curr Pharm Des. 2015; 21(4): 507-14. doi: 10.2174/1381612821041 41204144035. 23. Labbene I, Arrigo M, Tavares M, Hajjej Z, Brandao JL, Tolppanen H, et al. Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy. Anaesth Crit Care Pain Med. 2016. pii: S2352- 5568(16)30073-X. doi: 10.1016/j.accpm.2016.02.009. 24. Laliberte B, Reed BN, Ather A, Devabhakthuni S, Watson K, Lardieri AB, et al. Safe and effective use of pharmacologic and device therapy for peripartum cardiomyopathy. Pharmacotherapy. 2016; 36(9): 955-70. doi: 10.1002/phar.1795. 25. Levy B, Perez P, Perny J, Thivilier C, Gerard A. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med. 2011; 39: 450–5. doi: 10.1097/CCM.0b013e3181ffe0eb. 26. Mebazaa A, Tolppanen H, Mueller C, Lassus J, di Somma S, Baksyte G, et al. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. Intensive Care Med. 2016; 42(2): 147–63. doi: 10.1007/s00134- 015-4041-5. 27. Sheppard R, Rajagopalan N, Safirstein J, Briller J. An update on treatments and outcomes in peripartum cardiomyopathy. Future Cardiol. 2014. 10(3), 435–47. doi:10.2217/fca.14.23. 28. Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation. 2005;112:3577–83. doi: 10.1161/Circulationaha.105.542894. 29. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from Heart Failure Association of European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010; 12(8): 767-78.doi: 10.1093/eurjhf/hfq120. 30. Stapel B, Kohlhaas M, Ricke-Hoch M, Haghikia A, Erschow S, Knuuti J, et al. Low STAT3 expression sensitizes to toxic effects of βadrenergic receptor stimulation in peripartum cardiomyopathy. Eur Heart J. 2016; ehw086. doi: 10.1093/eurheartj/ehw086